Synthetic Biologics, Inc. (NYSE: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that it ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE